These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7816864)
1. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Derrien M; McCort-Tranchepain I; Ducos B; Roques BP; Durieux C Pharmacol Biochem Behav; 1994 Sep; 49(1):133-41. PubMed ID: 7816864 [TBL] [Abstract][Full Text] [Related]
2. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide. Boyle SJ; Tang KW; Woodruff GN; McKnight AT Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944 [TBL] [Abstract][Full Text] [Related]
3. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Lemaire M; Böhme GA; Piot O; Roques BP; Blanchard JC Psychopharmacology (Berl); 1994 Aug; 115(4):435-40. PubMed ID: 7871086 [TBL] [Abstract][Full Text] [Related]
4. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites. Léna I; Roques BP; Durieux C J Neurochem; 1997 Jan; 68(1):162-8. PubMed ID: 8978722 [TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Derrien M; Noble F; Maldonado R; Roques BP Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353 [TBL] [Abstract][Full Text] [Related]
6. Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat. Léna I; Simon H; Roques BP; Daugé V Neuropharmacology; 1999 Apr; 38(4):543-53. PubMed ID: 10221758 [TBL] [Abstract][Full Text] [Related]
7. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314 [TBL] [Abstract][Full Text] [Related]
8. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Crawley JN J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584 [TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Valverde O; Roques BP Neurosci Lett; 1998 Mar; 244(1):37-40. PubMed ID: 9578139 [TBL] [Abstract][Full Text] [Related]
10. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411 [TBL] [Abstract][Full Text] [Related]
11. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264. Durieux C; Ruiz-Gayo M; Roques BP Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561 [TBL] [Abstract][Full Text] [Related]
12. Effects of cholecystokinin octapeptide and BC 264, a potent and selective CCK-B agonist on aspartate and glutamate release from rat hippocampal slices. Migaud M; Roques BP; Durieux C Neuropharmacology; 1994 Jun; 33(6):737-43. PubMed ID: 7936111 [TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase. Ding XQ; Chen D; Håkanson R Gastroenterology; 1995 Oct; 109(4):1181-7. PubMed ID: 7557084 [TBL] [Abstract][Full Text] [Related]
15. The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Derrien M; Daugé V; Blommaert A; Roques BP Behav Brain Res; 1994 Dec; 65(2):139-46. PubMed ID: 7718145 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models. Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145 [TBL] [Abstract][Full Text] [Related]
17. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205 [TBL] [Abstract][Full Text] [Related]
18. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives. Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845 [TBL] [Abstract][Full Text] [Related]
19. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283 [TBL] [Abstract][Full Text] [Related]
20. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]